SAGE THERAPEUTICS, INC.

(SAGE)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
42.99 USD   +2.41%
08/03Goldman Sachs Adjusts Sage Therapeutics' Price Target to $73 From $74, Keeps Buy Rating
MT
08/03Citigroup Trims Price Target on Sage Therapeutics to $40 From $41, Maintains Neutral Rating
MT
08/03Wedbush Trims Price Target on Sage Therapeutics to $52 From $54, Keeps Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société SAGE THERAPEUTICS, INC.
08/02SAGE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
08/02SAGE THERAPEUTICS : Announces Second Quarter 2022 Financial Results and Highlights Pipelin..
PU
08/02Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeli..
BU
08/01Sage Therapeutics to Present at Upcoming August Investor Conferences
BU
07/19Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2,..
BU
07/14SAGE THERAPEUTICS : IF YOU DO NOT OBJECT TO THE PROPOSED SETTLEMENT, OR THE AGREED-TO ATTO..
PU
07/14SAGE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/21SAGE THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matters..
AQ
06/13SAGE THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
06/02Sage Therapeutics to Present at Upcoming June Investor Conferences
BU
06/01SAGE THERAPEUTICS : and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Po..
PU
06/01SAGE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/01Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in P..
BU
05/04Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference
BU
05/03SAGE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
05/03Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipelin..
BU
05/02Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) ..
BU
04/19Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 202..
BU
04/04Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY..
AQ
04/01Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY..
BU
03/22Sage Therapeutics to Present at 2022 Stifel CNS Days
BU
03/15Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADI..
BU
02/28Sage Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference
BU
02/24SAGE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
02/24SAGE THERAPEUTICS : Announces Fourth Quarter and Full Year 2021 Financial Results and High..
PU
02/24Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Hig..
BU
02/17Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key S..
AQ
02/16SAGE THERAPEUTICS : and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Se..
PU
02/16Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key S..
BU
02/16SAGE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
02/10Sage Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thur..
BU
01/10SAGE THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
01/04Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tu..
BU
2021Sage Therapeutics Third Annual FutureCast Showcases Data from All Three Brain Health Fr..
AQ
2021Sage Therapeutics' Third Annual FutureCast Showcases Data from All Three Brain Health F..
BU
2021Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Developm..
AQ
2021SAGE THERAPEUTICS : and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the On..
PU
2021SAGE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Sage Therapeutics to Host Sage FutureCast Webcast
BU
2021Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Confer..
BU
2021Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
BU
2021Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipelin..
PU
2021SAGE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
2021Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipelin..
BU
2021SAGE THERAPEUTICS : to Report Third Quarter 2021 Financial Results on Tuesday, November 2,..
BU
2021SAGE THERAPEUTICS : and Biogen Announce Plans to Submit a New Drug Application (NDA) for Z..
AQ
2021SAGE THERAPEUTICS : and Biogen Announce Plans to Submit a New Drug Application (NDA) for Z..
PU
2021SAGE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021SAGE THERAPEUTICS : and Biogen Announce Consistent Clinically Meaningful Data for Zuranolo..
BU
2021SAGE THERAPEUTICS : Launches SageCitizen Social Impact Initiative
BU
2021SAGE THERAPEUTICS : Appoints Chris Benecchi as Chief Commercial Officer
BU
2021SAGE THERAPEUTICS : Receives Fast Track Designation for SAGE-718 for the Treatment of Hunt..
AQ
2021SAGE THERAPEUTICS : Receives Fast Track Designation for SAGE-718 for the Treatment of Hunt..
BU
2021SAGE THERAPEUTICS : to Present at the Morgan Stanley Global Healthcare Conference
BU
2021SAGE THERAPEUTICS : to Present at Upcoming August Investor Conferences
BU
2021SAGE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Result..
AQ
2021SAGE THERAPEUTICS : Company announces REDWOOD and RAINFOREST Studies not expected to be re..
PU
2021SAGE THERAPEUTICS : Announces Second Quarter 2021 Financial Results and Highlights Pipelin..
BU
2021SAGE THERAPEUTICS : to Report Second Quarter 2021 Financial Results on Tuesday, August 3, ..
BU
2021SAGE THERAPEUTICS : to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsyc..
AQ
2021SAGE THERAPEUTICS : to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsyc..
BU
2021SAGE THERAPEUTICS : to Participate in SVB Leerink's 3rd Annual CNS Forum
AQ
2021SAGE THERAPEUTICS : to Participate in SVB Leerink's 3rd Annual CNS Forum
BU
2021Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone f..
AQ
2021SAGE THERAPEUTICS : and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone an..
AQ
2021Cracker Barrel, Sage Therapeutics fall; Ocugen, FedEx rise
AQ
2021SAGE THERAPEUTICS : to Host Conference Call
BU
2021SAGE THERAPEUTICS : and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, a..
PU
2021SAGE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021SAGE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2021SAGE THERAPEUTICS : Joins MTV Entertainment Group and More Than 1,300 Leading Organization..
BU
2021SAGE THERAPEUTICS TO HOST SAGE SCIEN : SAGE-718 In Depth
BU
2021SAGE THERAPEUTICS : Company on-track to initiate placebo-controlled Phase 2 trial with SAG..
PU
2021SAGE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Result..
AQ
2021SAGE THERAPEUTICS : Announces First Quarter 2021 Financial Results and Highlights Pipeline..
BU
1  2  3  4  5Next
Upcoming event on SAGE THERAPEUTICS, INC.